{"id":"abiraterone-prednisolone-prednisone","safety":{"commonSideEffects":[{"rate":"30–40","effect":"Hypertension"},{"rate":"15–25","effect":"Hypokalemia"},{"rate":"10–20","effect":"Fluid retention/edema"},{"rate":"30–40","effect":"Fatigue"},{"rate":"10–15","effect":"Joint pain/arthralgia"},{"rate":"10–15","effect":"Diarrhea"},{"rate":"10–15","effect":"Urinary tract infection"},{"rate":"5–10","effect":"Elevated liver enzymes"},{"rate":"5–10","effect":"Cardiovascular events"}]},"_chembl":{"chemblId":"CHEMBL271227","moleculeType":"Small molecule","molecularWeight":"391.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abiraterone acetate is a selective inhibitor of 17α-hydroxylase/17,20-lyase (CYP17A1), a key enzyme in androgen biosynthesis in the testes and adrenal glands. By blocking this enzyme, abiraterone reduces circulating testosterone and other androgens, which are critical for castration-resistant prostate cancer (CRPC) cell growth. Prednisolone or prednisone is co-administered to suppress compensatory ACTH-driven adrenal androgen production and to mitigate mineralocorticoid excess caused by shunting of steroid precursors.","oneSentence":"Abiraterone inhibits CYP17A1 to block androgen synthesis, while prednisolone/prednisone suppresses ACTH-driven adrenal compensation and provides anti-inflammatory effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:36.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC)"},{"name":"High-risk metastatic hormone-sensitive prostate cancer (mHSPC)"}]},"trialDetails":[{"nctId":"NCT06421935","phase":"PHASE1","title":"M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-08-07","conditions":"Advanced Solid Tumor","enrollment":141},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT07005154","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-06-19","conditions":"Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":218},{"nctId":"NCT04597125","phase":"PHASE4","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-11-09","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":654},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT03732820","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-31","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":895},{"nctId":"NCT06764485","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-03-13","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":960},{"nctId":"NCT04493853","phase":"PHASE3","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-13","conditions":"Hormone-Sensitive Prostate Cancer","enrollment":1012},{"nctId":"NCT05457257","phase":"PHASE4","title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer","enrollment":48},{"nctId":"NCT03568656","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 in Advanced Tumours","status":"COMPLETED","sponsor":"CellCentric Ltd.","startDate":"2018-07-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT02975934","phase":"PHASE3","title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2017-06-13","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":405},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT05288166","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-04-14","conditions":"Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms","enrollment":925},{"nctId":"NCT05401214","phase":"","title":"Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)","status":"APPROVED_FOR_MARKETING","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":""},{"nctId":"NCT03072238","phase":"PHASE3","title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-06-30","conditions":"Metastatic Prostate Cancer","enrollment":1101},{"nctId":"NCT03834519","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":793},{"nctId":"NCT06652607","phase":"","title":"PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-12-20","conditions":"Prostate Cancer, Metastatic Cancer, Castrate Sensitive Prostate Cancer","enrollment":152},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":"Prostatic Neoplasms","enrollment":806},{"nctId":"NCT05295927","phase":"PHASE1","title":"A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-03-23","conditions":"Prostatic Neoplasms","enrollment":3},{"nctId":"NCT06768255","phase":"PHASE3","title":"Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC","status":"NOT_YET_RECRUITING","sponsor":"Ding-Wei Ye","startDate":"2025-01-30","conditions":"Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer)","enrollment":400},{"nctId":"NCT01685268","phase":"PHASE1, PHASE2","title":"A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2012-09","conditions":"Prostate Cancer","enrollment":49},{"nctId":"NCT01972217","phase":"PHASE2","title":"Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":158},{"nctId":"NCT02987543","phase":"PHASE3","title":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-06","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":387},{"nctId":"NCT01995513","phase":"PHASE4","title":"Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-22","conditions":"Prostate Cancer","enrollment":509},{"nctId":"NCT01485861","phase":"PHASE1, PHASE2","title":"Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-01-11","conditions":"Prostate Cancer","enrollment":298},{"nctId":"NCT00268476","phase":"PHASE2, PHASE3","title":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical Research Council","startDate":"2005-07-08","conditions":"Prostate Cancer","enrollment":11992},{"nctId":"NCT01517802","phase":"PHASE3","title":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-03-28","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer","enrollment":32},{"nctId":"NCT03551782","phase":"PHASE1","title":"A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-06-28","conditions":"Castration-Resistant Prostatic Neoplasms","enrollment":33},{"nctId":"NCT02737332","phase":"PHASE2","title":"A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2016-03-21","conditions":"Prostate Cancer","enrollment":53},{"nctId":"NCT02867852","phase":"PHASE2","title":"Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2015-03","conditions":"Salivary Glands Tumors","enrollment":24},{"nctId":"NCT04736108","phase":"PHASE2","title":"Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2021-05","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT01381874","phase":"PHASE2","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-08-24","conditions":"Metastatic ER+ Her2- Breast Cancer, Postmenopausal","enrollment":297},{"nctId":"NCT01834209","phase":"","title":"A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Prostate Neoplasms","enrollment":""},{"nctId":"NCT01217697","phase":"","title":"Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer","status":"APPROVED_FOR_MARKETING","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Prostate Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms","enrollment":""},{"nctId":"NCT01692483","phase":"","title":"Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"Janssen Pharmaceutica","startDate":"2013-07","conditions":"Prostate Neoplasms","enrollment":""},{"nctId":"NCT00474383","phase":"PHASE2","title":"An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy","status":"COMPLETED","sponsor":"Cougar Biotechnology, Inc.","startDate":"2006-11","conditions":"Prostate Neoplasms","enrollment":47},{"nctId":"NCT00638690","phase":"PHASE3","title":"Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy","status":"COMPLETED","sponsor":"Cougar Biotechnology, Inc.","startDate":"2008-05","conditions":"Prostatic Neoplasms","enrollment":1195},{"nctId":"NCT00473746","phase":"PHASE1, PHASE2","title":"Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2006-06","conditions":"Prostate Neoplasms","enrollment":66},{"nctId":"NCT00485303","phase":"PHASE2","title":"An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy","status":"COMPLETED","sponsor":"Cougar Biotechnology, Inc.","startDate":"2007-06","conditions":"Prostatic Neoplasms, Prostate Cancer","enrollment":58},{"nctId":"NCT01664728","phase":"PHASE1","title":"An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2007-04","conditions":"Prostate Neoplasms","enrollment":54},{"nctId":"NCT00600535","phase":"PHASE1","title":"A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Cougar Biotechnology, Inc.","startDate":"2007-07","conditions":"Prostate Neoplasms","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abiraterone + Prednisolone/Prednisone","genericName":"Abiraterone + Prednisolone/Prednisone","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abiraterone inhibits CYP17A1 to block androgen synthesis, while prednisolone/prednisone suppresses ACTH-driven adrenal compensation and provides anti-inflammatory effects. Used for Metastatic castration-resistant prostate cancer (mCRPC), High-risk metastatic hormone-sensitive prostate cancer (mHSPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}